Monthly Prescribing Reference

Apixaban Bests Rivaroxaban in “Emulated” Trial of Patients With Afib and VHD

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...
MedPage Today

Eliquis vs Xarelto: Which Is Better in Afib?

Choice of direct oral anticoagulant (DOAC) mattered for clinical outcomes among adults with atrial fibrillation (Afib), a study based on U.S. insurance claims found. Apixaban (Eliquis) users had ...
MedPage Today

Apixaban Has Edge Over Other OACs for Older HIV Patients With Afib

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...
Monthly Prescribing Reference

Study Compares Rivaroxaban, Warfarin With Apixaban for Cirrhosis, A-Fib

Initiators of rivaroxaban or warfarin vs apixaban have significantly higher rates of major hemorrhage. HealthDay News — For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators ...
TCTMD

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

The use of apixaban (Eliquis; Bristol-Myers Squibb) over rivaroxaban (Xarelto; Bayer/Janssen) in patients with atrial fibrillation (AF) and valvular heart disease is associated with better clinical ...
Nasdaq

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist ...

Anticoagulants, like NOACs and warfarin, are prescribed to people with NVAF to reduce their risk of stroke. In the 2019 update of the AHA/ACC/HRS Guidelines for the Management of Patients with Atrial ...
TCTMD

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...
Medscape

Rivaroxaban Tied to Higher Bleeding, Events vs Apixaban in AF

Results of a large-scale observational study show that among patients aged 65 or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly ...
Nasdaq

XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World ...

NEW ORLEANS, March 18, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new real-world study, which found newly diagnosed patients with ...
Healio

Apixaban linked to fewer adverse events in older adults with frailty, atrial fibrillation

Please provide your email address to receive an email when new articles are posted on . Among older adults with atrial fibrillation, apixaban was linked to lower rates of adverse events across all ...
Business Insider

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist ...

TITUSVILLE, N.J., March 11, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from a large, real-world meta-analysis of 95 studies ...